World EPA Congress 2025 | Terrapinn | 4 March 2025 | RAI Congress Centre, Amsterdam, Europaplein 24, 1078 GZ Amsterdam, Netherlands

Covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes research in healthcare. 90+ leading solution producers to meet your needs across evidence generation, market access, pricing, rare diseases and more to enable operational excellence.

Networking is at the heart of the World Evidence Pricing and Access Congress. Our congress allows you to connect directly with key decision makers across 2 days of built in one to one networking.

2025 Speakers

Kate Adcock
Director Of Research And Innovation, The Muscular Dystrophy U.K.

Kevyn Adler
Senior Director, Market Access Product & Pipeline Strategy, Regeneron

Mehmet Aksözen
Economist and Data Scientist, International Porphyria Patient Network

Tommaso Albonetti
CEO, RxData, Inc.

Ana Filipa Alexandre
Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals

Eunice Alvazzi
Head of Global Value & Access, Hematology, Nephrology & Neurology, Alexion – AstraZeneca Rare Disease

Marta Andreykiv
Head of Market Access Europe, Viatris

Ad Antonisse
Director, Market Access & Corporate Affairs, AstraZeneca

Sabrina Aouabed
Head of Market Access France, GSK

Jose Aragunde
Value and Pricing Strategy Lead, Market Access, Novartis

Jorge Arellano
Vice President, Head of Intercontinental Markets, Market Access, Pricing, & Value Demonstration, Bristol Myers Squibb

Marnix Artz
Head of Patient Access, Value & Government Affairs, Merck Group

Carl Asche
Executive Director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy

Nikki Atkins
Executive Director and Practice Lead, Global Patient Access Strategy and Commercialization, Avalere Health

Nico Bacharidis
Chief Commercial Officer, CUBE RM

Lianne Barnieh
Associate Director, HEOR, BeiGene

Ahmad Bechara
EVP, Alira Health

Tomer Benzaken
Director, Head of Commercial Operations & Trade, Astellas

Katja Berg
Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca

Ingrid Bettum
Senior Adviser, Unit for HTA Cancer Medicines, Norwegian Medicines Agency

Chris Bidad
Global Head, Access Strategy and Payer Policy, AstraZeneca

Matthias Bischof
Senior Director, International Health Economics, Novartis

Nerea Blanqué-Catalina
Senior Partner Pricing, Access and Sustainability, Alira Health

Slobodanka Bolanca
Head of Global Market Access Implementation for Established Markets (Europe, UK, Canada), Astellas

Thomas Bols
Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics

Angela Borghouts - de Ruijter
Senior Pricing and Market Access Manager, Cell Therapy, Gilead Sciences

Kinga Borsos
Vice President, Head of US HEOR, Boehringer Ingelheim

Okke Bosgra
Director, International Market Access, Natera

Claire Boskamp
Senior Director GOVAP Analytics, Operational and Payer Excellence, Daiichi Sankyo

Meindert Boysen
Independent HTA Expert & Chair, HTAi Global Policy Forum

Vidya Breeveld
CEO, Transmineo

Chiara Brouns
Strategic Purchaser, Zorgverzekeraars Nederland

Sangeeta Budhia
Vice President, Global Head of Pricing & Market Access, Parexel

Henriette Burghoorn
Associate Director, Market Access, Gilead

Thomas Butt
Executive Director, Health Economics & Outcomes Research, Biomarin

Frederico Calado
Real-World Data Strategic Partnership Lead, Sanofi

Sam Calderwood
Associate Principal, Blue Matter Consulting

Silvia Miriam Cammarata
Senior Regulatory Affairs and Health Policy Specialist, AIFA Italian Medicine Agency

Gorana Capkun
Vice President, Global Head of Patient Focused Real World Evidence, Merck Group

Joao Carapinha
Director & Professor, Syenza & Northeastern University

Antonella Cardone
CEO, Cancer Patients Europe

David Carr
Senior Director, Strategic Consulting, Precision AQ

Maria Cavaller Bellaubi
Patient Engagement and Therapeutic Development Director, EURORDIS

Mark Cawley
Associate Director, R&D Procurement, Jazz Pharmaceuticals

Sandro Cesaro
Head of Europe Market Access & Pricing, AstraZeneca

Betty Charleshouse
Market Access Director, AMICULUM

Helene Chevrou-Severac
Senior Director, RWE & Outcomes Centre of Excellence Head, Alexion – AstraZeneca Rare Disease

Jagpreet Chhatwal
Director, Institute for Technology Assessment, Harvard Medical School, Massachusetts General Hospital

Sania Chouman
Global Head of Access Innovation, Takeda

Sally Chung
Vice President, Value & Access International Operations & Excellence, Ipsen

Oriana Ciani
Associate Professor of Practice, SDA Bocconi

Warren Cowell
Director, Market Access UK, Shionogi Ltd

Don Creighton
Executive Director, Market Access Pipeline and Readiness Lead, Regeneron

Alan Crowther
General Manager, Global Pricing & Access, Eversana

Florian Csintalan
Senior Consultant Market Access Strategy, Clinigen Group

Rachel Daley
Patient Advocate, University of Liverpool

Rishi Das-Gupta
Chief Executive Officer, Health Innovation Network

Dalia Dawoud
Associate Director, Research, NICE

Marie-Monique de Molliens
Global Market Access Horizon Scanning Senior Director, Sanofi

Emanuele Degortes
Vice President, Global Head of Access Policy and Patient Advocacy, Menarini

Eelko Den Breejen
Senior Director, Global Access Strategy & Pricing Oncology Team Lead, Portfolio & Market Engagement, Pfizer

Rossella Di Bidino
Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS

Olga Diachenko
Director Market Access, EMENA, Accord Healthcare

Eva Susanne Dietrich
Professor, Departments for Clinical Pharmacy and Regulatory Affairs, University of Bonn

Toon Digneffe
Head Public Affairs & Public Policy, Takeda

Riad Dirani
Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals

Filippo Drago
Full Professor of Clinical Pharmacology, University of Catania

Maurice Driessen
Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals

Marcus Droege
Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Richard Dutton
Director, Dolon

Fredrik Eisner
Senior Director, Pricing & Market Access, Parexel

Shane Elder
Head of Market Access, Europe & Canada, AstraZeneca

Ruven Remo Eul
Principal and Chief Commercial Officer, Marbls

Marc Evans
Consultant Diabetologist, University Hospital Llandough

Claire Everitt
Design Engineering Team Lead, IMI Project Leader, Pfizer

Gina Ewy
VP, Hansa Biopharma

Barry Farrimond
Managing Principal, Global Value & Access Strategy and Solutions, ZS

Judith Fernandez
Deputy Director, HTA Department, French Authority for Health (HAS)

Girisha Fernando
CEO, Lyfegen

Tina Fischer
Head of Health Technology Assessments, Oncology, Daiichi-Sankyo

Mary Fletcher-Louis
Managing Director & Head of Value Center of Excellence, Trinity Life Sciences

Steven Flostrand
Executive Director, Value, Access & Pricing, Incyte Corp.

Graham Foxon
Managing Director, Remap Consulting

Neil Gallagher
Director, Copenhagen Economics

Martina Garau
Director, Office of Health Economics

Loic Gauthier
Global Pricing Director, CSL Behring

Philippe Ghyssels
Vice President, Global Public Affairs, Ipsen

Fabrizio Gianfrate
Full Professor, Health Economics and Outcomes Research, University Of Rome

Ramiro Gilardino
Associate Professor of Public Health, Buenos Aires School of Public Health

Mathieu Gilbert
Chief Operating Officer, Adocia

Thomas Gilboy
Product Owner, Access Infinity

Christoph Glaetzer
Chief Global Value and Access Officer, Johnson & Johnson

Wim Goettsch
Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut & Utrecht University

Jean Christophe Goirand
Senior Director, Global Head Market Access & Pricing, Essential Pharma

Ewelina Golebiewska
European Companion Diagnostic (CDx) Market Access Lead, Menarini Stemline

Adam Gordois
Director, HEOR & Value Demonstration, BioCryst Pharmaceuticals

Sofiya Got
Strategy and Transformation Analyst, NHS

Sylvie Greneche
Head of Global Market Access, General Medicines, Sanofi

Alex Grosvenor
Senior Vice President, Managing Director of Strategic Consulting, Precision AQ

Thomas Grub
Director Global Pricing and Market Access, medac GmbH

Neil Grubert
Global Market Access Expert, Independent

Josep M Guiu
Director, Pharmacy and Medicines Area, Consortium of Health and Social Care of Catalonia

Marlene Gyldmark
EU HTA Lead, BeiGene

Matthew Hanchard
Research Fellow, University of Sheffield

Sabina Heinz
Senior Principal, Market Access Europe, Ipsos Market Access

Paul Henricks
Associate Director, Data Innovation, PDCI Market Access Inc

Charlie Hewitt
Associate Director, Remap Consulting

Patrick Hopkinson
Independent HTA Expert

Martí Hopmans
Senior Global Market Access Manager, Ferrer International

Christina Hoxer
Vice President, Global Head of Diabetes Market Access, Novo Nordisk

Kirsty Hoyle
CEO, Metabolic Support UK

Jurgen Huismans
Director, HTA Strategy & Policy, MSD Innovation & Development GmbH

Elke Hunsche
Vice President, Global Market Access & Health Economics / Outcomes Research, Sumitomo Pharma Switzerland GmbH

Dawn Ireland
President, CDH International

Amy Israel
Senior Advisor, Access to Medicines, Union for International Cancer Control

Jayasree Iyer
Chief Executive Officer, Access to Medicine Foundation

Daniel Jackson
Global Head, Payer Evidence Synthesis, UCB

Mohit Jain
Vice President, Market Access, International Operations, IntraBio

Christel Jansen
Director, Inbeeo

Grace Jennings
Senior Director, Outcomes Research, ICHOM

Navin Joshi
Vice President, Lifescience Dynamics Ltd

Ariadna Juarez
Real World Evidence and Health Economics Outcomes Director, Mereo Biopharma

Stephanie Juniat
Independent Market Access Expert

Iroda Jurabekova
Global Director, Oncology Pricing and Market Access, Boehringer Ingelheim

Madhu Kabra
Global Director, HEOR & RWE, MKGlobal

Ankita Kaushik
Senior Director, HEOR, Global Value and Access, Gilead Sciences

Angela (Angie) Kehagia
Deputy Director, Senior HTA, KiTEC King's Technology Evaluation Centre

Tom Kelly
Director, Dolon

Sandeep Kiri
Global Head, Health Economic Evidence, UCB

Sven Klijn
Director, HEOR Economic & Predictive Modeling, Bristol Myers Squibb

Jutta Kloppenborg Heick Skau
Product Creator in the Transformational Prevention Unit, Novo Nordisk

Tomasz Kluszczynski
Strategy Consultant & Founder, ACESO Healthcare

Helen Knight
Director of Medicines Evaluation, NICE

Amit Kulkarni
Head of Health Economic Modeling and Decision Sciences, Otsuka

Adam Kundzewicz
Head of Market Access and Healthcare Affairs, Boehringer Ingelheim

Hannah Kurth
Founder and Managing Director, Pulse Edge

Walmon Leal
Head of Global Pricing, Viatris

Gavin Lewis
Senior Vice President, Head of Value and Access, Novartis

Pauline L'Hénaff
Head of Industry Engagement, Access to Medicine Foundation

Stefano Losi
Market Access Lead, Europe & Emerging Markets, Chiesi Group

Ning Lu
Director, International Market Access and Pricing, Blueprint Medicines

Manuela Machado
Head of Europe Access, Sustainability & External Engagement, UCB

Silvia Maeso
Vice President, Global Market Access, Health Economics, Pricing and HTA, Almirall, S.A.

Charles Makin
Head of RWE, Boehringer Ingelheim

Bill Malcolm
Executive Director, Global HEOR Economic & Predictive Modelling, BMS

Chris Mancill
Senior Vice President, Head, US Market Access, AstraZeneca

Chiara Mangiaracina
Market Access Lead EU & EM, Chiesi Farmaceutici

Timothy Mann
Director, Market Access, Jazz Pharma

Andrea Mantovani
Partner, Integrated Evidence Consulting, Alira Health

Marco Marchetti
Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy

Silvy Mardiguian
Senior Director, Head of HEOR, Europe & New Markets, BeiGene

Sandra Margunato-Debay
Senior Director, Global Market Access, Genmab

Marisca Marian
Oncology Access Strategy Lead, Bayer

Alen Marijam
Senior Director, Vaccines, HEOR and Epidemiology Lead, Europe, GSK

David McConkey
Partner, Access Infinity

Phil McEwan
CEO, HEOR

Vivian Mendonca
Senior Vice President, Global Head - Value Evidence and External Affairs (G-VEEA), Menarini Group

Susanne Michel
Head of HTA Methods and Evidence Planning, Clinigen

Paul Miller
Director, Miller Economics

Vanessa Mirsky
Vice President, Life Sciences Data Strategy, OneOncology

Lorenzo Montrasio
Member of Volrethics Steering Committee, Former Council of Europe

Daniel Moreira
CEO & Co-founder, Cellbyte

Paolo Morgese
Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine

Tiyi Morris
Health Economist, Initiate Consultancy

Philippe Mourouga
Vice President, International Partner Markets, Biogen

George Mullens
Project Manager, Terrapinn Holdings Ltd

Andrew Mumford
Chief Executive Officer, Initiate Consultancy

Hidde Nab
Associate Director, Innovation & Strategy, Asc Academics

Alexander Natz
Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Antonia Needham-Taylor
Health Services Researcher, Health Technology Wales

Anh Bourcet Nguyen
Senior Director, Market Access & Public Affairs, APAC, Novo Nordisk

Enkeleida Nikai
Vice President, Head of Global Real-World Evidence, GenMed, Sanofi

Eric Noehrenberg
Independent Market Access Expert

Esther Nzenza
Founder & CEO, Decisive Consulting Ltd.

Andrew Olaye
Head of EMEA Market Access, Orchard Therapeutics Ltd

Melvin Skip Olson
Founder, Olson Strategies GmbH

Wija Oortwijn
Chair of Appraisal Committee, ZINL & Assistant Professor, HTA, ZIN & Radboud University Medical Center

Ipek Ozer-Stillman
Vice President, Global Head, Health Economics, Takeda

Elena Panitti
Global Director, Evidence Valuation and Enablement, Novartis

Michela Pantaleoni
Chief Market Access Officer, Napo Therapeutics

Andrea Parodi
Executive Vice President, Head of Biostatistics, Valos Srl

Lotta Parviainen
Head of Global Market Access, Zambon France

Dilip Patel
SVP, Pricing, Value & Access Strategy, Autolus

Thirupathi Pattipaka
Global Director, Data Science and AI, Novartis

Peter Pemberton-Ross
Head, HE & HTA Strategy, Biogen International GmbH

Marco Penske
Head, Market Access & Healthcare Affairs, Germany, Boehringer Ingelheim

Trine Pilgaard
Director, Head of Market Access, Denmark and Iceland, Pfizer

Oresta Piniazhko
Director, HTA Department of State Expert Center, Ministry of Health, Ukraine

Carme Pinyol
Early Products and HEOR Lead, Novartis

Lara Pippo
Head of Market Access & Government Affairs, Italy, CSL Behring

Luca Luigi Polastri
Global Value and Access Head, Nephrology Franchise, Kyowa Kirin

Annette Powers
Senior Vice President, Global Market Access, Bristol Myers Squibb

Arup Pramanik
Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim

Eugenia Priedane
Director, Global HEOR and Evidence Strategy, BeiGene

Chris Prins
Policy Advisor Expensive Medicines, Zorgverzekeraars Nederland

Jennifer Quinn
Head of Global Value and Access, Debiopharm International

Rafaat Rahmani
President & Founder, Lifescience Dynamics Ltd

Jonathan Randell
Head of Value and Access, UK & Ireland, Biogen

Andrea Rathmann-Schmitz
Managing Director, MEDAHCON (Medical and Healthcare Content)

Vijay Reddy
Chief Commercial Officer, Avinya Biotech

Edit Remak
Partner and Director of Health Economics, Visible Analytics Ltd.

Casey Rhode
Head of Strategy, OneOncology

Andreia Ribeiro
Associate Principal of Value, Access and Pricing, Trinity Life Sciences

Sandra Rose
Head of Market Access & Public Affairs, Chiesi

Laura Roulston
Manager, Market Access and Forecasting, PDCI Market Access Inc

Jean Louis Roux
Global Public Affairs and Communications, Ferring

Isabel Rubio
Director, Access Infinity

Sandrine Ruiz
Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd

Claus Runge
Chief Health Equity Officer, Senior Vice President, Global Head of Public Affairs, Sustainability & Int. Engagement, Bayer

Maureen Rutten-van Mölken
Professor of Economic Evaluation of Innovations for Health, Erasmus University Rotterdam

Bettina Ryll
Founder, Melanoma Patient Network Europe, MPNE

José Luis Sánchez
Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals

Marie Sanderson
Head of Value and Access Europe, Novartis

Steve Sandor
Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals, Inc.

Raquel Santos
Manager, Marbls

Gustavo Saraiva dos Anjos
Head of Pricing and Market Access Europe, Teva

Fabian Schmidt
Global Head of Market Access, HEOR and Policy, Recordati Rare Diseases

Matthias P. Schönermark
Chief Corporate Development Officer, Kintiga

Smita Sealey
Principal, ZS

Ayman Semaan
Market Access & Pricing Lead, Biologix

Shuvayu Sen
Vice President, Head of Oncology, Center of Observational & Real-World Evidence, Merck & Co., Inc.

Hans Severens
Independent HTA Expert, Severens HTA Consultancy

Sugandh Sharma
Executive Director, HEOR: Evidence Evaluation, Parexel International

Simon Shohet
Vice President, International Market Access, Amicus Therapeutics

Anupama Rao Singh
Group Country Head - LATAM | Head - Oncology and Hospital Business CoE, Emerging Markets, Dr. Reddy's Laboratories Ltd.

Matt Slabbert
Vice President, Global Head of Public Affairs, Astellas

Najib Slassi
Commercial Director - Gene Therapies, Novartis

Paul Slobbe
Director, Market Access and External Affairs, Takeda Nederland

Jiri Smejkal
Head of Pricing and Tender Excellence PDT, Takeda

Igor Solev
Global Head, Market Access, Policy & External Payer Affairs, Abbott Laboratories

Seema Sondhi
Independent Market Access Expert

Manoj Sood
Commercial Access Director, Independent Market Access Expert

Wayne Speechly
Chief Executive Officer, Global Pricing Innovations

Nadine Sprangers
Vice President, Head of Global Oncology Value, Access and Pricing, Daiichi Sankyo

Jan Swiderski
Director, Head of Global Public Affairs and Advocacy, Ipsen

Peter Takacs
Head of Global Market Access, Miltenyi Biomedicine

Neeta Tandon
Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation

Gabriela Taschke
Senior Director EU ASEE Rare + Epilepsy, UCB

Ivo Timmermans
Founder & Co-CEO, Pleco Therapeutics

Mondher Toumi
Professor of Public Health, Aix-Marseille University

Catrin Treharne
Health Economics Lead, LCP

Elena Tricca
Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca

Emmanouil Tsiasiotis
Research Project Manager and Coordinator, EDiHTA

Kaan Tunceli
Vice President and Head, Global Value and Real-World Evidence, Otsuka Pharmaceutical

Nicole Tunstall
Vice President, International Market Access Consulting, GmbH

Aodan Tynan
Vice President, Global Market Access, Astellas

Carin Uyl-de Groot
Professor of HTA, Erasmus University Rotterdam

Cristina Valencia
Associate Director, Real World Evidence, Takeda

Goedele van Haasteren
Deputy Chief of the HTA Department, Federal Office of Public Health, Switzerland

Chantal van Litsenburg
Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)

Mary Lynne van Poelgeest-Pomfret
President, World Federation for Incontinence and Pelvic Problems (WFIPP)

Jackie Vanderpuye-Orgle
Vice President, Global Head of Advanced Analytics, Parexel

Christina Vandorou
Director, Macroeconomics and Health Policy, EMEA, Johnson & Johnson Innovative Medicine

Oliver Viehmann
Principal and Practice Group Leader Pharma & Life Sciences, TWS Partners

Ilaria Villa
Chief Executive Officer, Fondazione Telethon

Rosa Maria Vivanco Hidalgo
Head of HTA, AQuAS Gencat

Pamela Vo
Vice President, HEOR, Value & Evidence, Eversana

Reg Waldeck
Vice President, Head Global Market Access, Bayer

Louwrens Wendelaar Bonga
Commercial Development Director, Pfizer

Richard Wenzel
Director, Global Pricing and Access Consulting, Eversana

Adam Weston
Executive Director, US and Global Pricing and Market Access Strategy, Genesis Research Group

Amanda Whittal
Associate Director, Dolon Ltd

Thomas Wilke
Senior Scientific Lead, GIPAM

Marjan Willaert
Policy Advisor, Market Access, pharma.be

Rhys Williams
Vice President, Evidence Generation Strategy and Health Economics, Global Medical Affairs (ex-China), BeiGene

Amy Winnen
Vice President, Strategic Partnerships, Aesara

Schiffon Wong
Vice President and Head, Neurology & Immunology, Global Value Demonstration, EMD Serono

2025 Sponsors

SILVER SPONSOR:
• Turacoz

TITLE SPONSOR:
• ZS

DIAMOND SPONSORS:
• Lifescience Dynamics
• Parexel
• Valid Insight

PLATINUM SPONSORS:
• AliraHealth
• Eversana
• Lyfegen
• Deloitte
• Remap
• Rednucleus

GOLD SPONSORS:
• Ascenian
• Decisive Consulting
• Genesis Research
• Global Pricing
• Kintiga
• Gipam
• Inbeeo
• Evidence
• Precision AQ
• Stratence Partners
• Stratenym
• Trinity

SILVER SPONSORS:
• Aesara
• Avalere Health
• Amiculum
• ASC Academics
• Blue|Matter
• CRA
• CE
• Cube
• Heor
• Ipsos
• IQVA
• Dolon
• Estima
• LCP
• Syenza
• Initiate
• Marbls
• International Market Access Consulting
• McKesson|PDCI
• Pharma Business PArtners
• Redthread
• RX Data
• TWS Partners
• Valos
• Visible Analytics